5th October 2016 marked the launch of the DiaTech Oncology TPA investment opportunity. DiaTech Oncology TPA Limited, the company set up to fund the final trials and commercialisation of the CEER platform developed by Pierian Biosciences, has now produced the final Information Memorandum that was made available to qualifying investors on 5th October. The unique CEER technology was brought to DiaTech from Nestlé in a deal announced on September 20th, 2016.
Funding is through the purchase of Redeemable Preference Shares. The opportunity is only available to high net worth investors, sophisticated investors and investment professionals. For more information about investing contact us.